Welcome!

News Feed Item

Omega Protein Announces Second Quarter 2014 Financial Results

HOUSTON, Aug. 6, 2014 /PRNewswire/ -- Omega Protein Corporation (NYSE: OME), a nutritional product company and a leading integrated producer of omega-3 fish oil and specialty protein products,  today reported financial results for the second quarter ended June 30, 2014.

Omega Protein Corporation Logo.

Second Quarter Highlights

  • Revenues:  $71.9 million for the quarter, compared to $41.8 million in the same period a year ago
  • Gross profit margin:  28.4% for the quarter, compared to 31.8% in the same period a year ago
  • Net income: $6.6 million, or $8.3 million excluding plant closure charges and gain on disposal of assets for the quarter, compared to $4.0 million in the same period a year ago
  • Earnings per diluted share: $0.31, or $0.38 excluding plant closure charges and gain on disposal of assets for the quarter, compared to $0.19 in the same period a year ago
  • Adjusted EBITDA:  $18.3 million for the quarter, compared to $11.8 million in the same period a year ago

"We are pleased with our solid performance in the second quarter. Positive supply and demand fundamentals in our animal nutrition segment fueled our strong revenue and earnings performance," commented Bret Scholtes, Omega Protein's President and Chief Executive Officer.  "Even though we experienced short-term challenges in our human nutrition segment in the quarter, we believe our diversified nutritional business continues to evolve and provide us with the opportunity to take advantage of growing demand for quality health and wellness products."

Second Quarter 2014 Results

The Company's revenues increased 72% from $41.8 million in the same period last year to $71.9 million.  This increase was due to a $30.8 million increase in animal nutrition revenues, partially offset by a $0.7 million decrease in human nutrition revenues.  The increase in animal nutrition revenues was primarily due to increased sales volumes of 43% and 482% for the Company's fish meal and fish oil, respectively, and increased sales prices for the Company's fish meal of 1%, partially offset by decreased sales prices of 37% for the Company's fish oil.  The decrease in fish oil sales prices was primarily due to a change in the product mix of higher priced refined and lower priced crude oils.  The decrease in human nutrition revenues was primarily due to lower Omega-3 tolling and other nutraceutical sales, partially offset by an increase in sales of protein products. The composition of revenue by nutritional product line for the second quarter of 2014 was 52% fish meal, 38% fish oil, 9% dietary supplements and food, and 1% fish solubles and other. 

Second quarter of 2014 revenues increased 13% from $63.5 million in the first quarter of 2014 to $71.9 million.  This increase was due to an increase in animal nutrition revenues of $10.0 million, partially offset by a $1.6 million decrease in human nutrition revenues. The increase in animal nutrition revenues was primarily due increased sales volumes of 36% and 4% for the Company's fish meal and fish oil, respectively, and increased sales prices for the Company's fish oil of 2%, partially offset by decreased sales prices of 4% for the Company's fish meal.  The decrease in human nutrition revenues was primarily due to lower Omega-3 and other nutraceutical sales.

The Company reported gross profit of $20.4 million, or 28.4% as a percentage of revenues, for the second quarter of 2014, versus $13.3 million, or 31.8% as a percentage of revenues, in the second quarter of 2013. The decrease in gross profit as a percentage of revenues was due to reductions in both the animal and human nutrition segments.  Animal segment gross profit as a percentage of revenues declined from 33.9% to 30.3%, due in part to a higher cost per unit for current season production.  Human nutrition gross profit as a percentage of revenues decreased to 9.9% from 22.1% due primarily to higher raw material and other protein product costs and lower tolling revenues.

Compared to the first quarter of 2014, second quarter gross profit decreased from $20.5 million, or 32.3% as a percentage of revenues, to $20.4 million, or 28.4% as a percentage of revenues.  Animal nutrition gross profit as a percentage of revenues decreased from 34.6% to 30.3%, primarily reflecting a higher cost per unit for current season production.  Human nutrition segment gross profit as a percentage of revenues decreased from 16.9% to 9.9% due largely to Omega-3 fish oil ingredients and tolling results.

Selling, general and administrative expenses for the second quarter increased $0.5 million to $6.5 million compared to the second quarter of 2013, primarily as a result of higher employee related and professional services expenses.  Selling, general and administrative expenses increased $0.4 million from $6.1 million in the first quarter of 2014.

In the fourth quarter of 2013, the Company closed its menhaden fish processing plant located in Cameron, Louisiana and re-deployed certain vessels from that facility to the Company's other Gulf Coast facilities located in Abbeville, Louisiana and Moss Point, Mississippi.  In conjunction with the closure, the Company incurred charges of $2.6 million in the second quarter of 2014 and $1.3 million in the first quarter of 2014.  

The second quarter of 2014 effective tax rate was 36.9% compared to 34.7% in the second quarter of 2013 and 33.9% in the first quarter of 2014.

Net income for the second quarter of 2014 was $6.6 million ($0.31 per diluted share) compared to $4.0 million ($0.19 per diluted share) in the same period last year and $8.0 million ($0.37 per diluted share) for the first quarter of 2014. Excluding plant closure charges and gain or loss on disposal of assets, net income for the second quarter of 2014 would have been $8.3 million ($0.38 per diluted share), compared to $4.0 million ($0.19 per diluted share) in the same period last year and $9.0 million ($0.42 per diluted share) for the first quarter of 2014.

Adjusted EBITDA totaled $18.3 million for the second quarter of 2014, compared to $11.8 million for the same period last year and $19.1 million for the first quarter of 2014.

Six Month 2014 Results

Revenues in the first six months of 2014 increased 49% to $135.4 million compared to revenue of $90.7 million for the six months ended June 30, 2013. The increase in revenues was due to a $43.7 million increase in animal nutrition revenues and a $1.0 million increase in human nutrition revenues. The increase in animal nutrition revenues was primarily due to increased sales volumes of 15% and 187% for the Company's fish meal and fish oil, respectively, and increased sales prices for the Company's fish meal of 8%, partially offset by decreased sales prices of 12% for the Company's fish oil.  The increase in human nutrition revenues was due primarily to sales of protein products from Wisconsin Specialty Protein, a business acquired by the Company in the first quarter of 2013.

The Company recorded gross profit of $40.9 million, or 30.2% as a percentage of revenues, for the first six months of 2014, versus gross profit of $25.4 million, or 28.0% as a percentage of revenues, for the first six months of 2013.  The increase in gross profit as a percentage of revenues was primarily due to the increase in animal segment sales prices, partially offset by a decrease in human nutrition gross profit as a percentage of revenues.

The effective tax rate was 35.3% for the six months ended June 30, 2014 compared to 34.1% for the six months ended June 30, 2013.

Net income for the six months ended June 30, 2014 was $14.6 million ($0.68 per diluted share) compared to $6.8 million ($0.33 per diluted share) for the same period last year.  Excluding the impact of the plant closure and loss on disposal of assets, net income for the six months ended June 30, 2014 would have been $17.3 million ($0.80 per diluted share) compared to $7.1 million ($0.34 per diluted share).

Adjusted EBITDA totaled $37.4 million for six months ended June 30, 2014, an increase from $21.8 million for the same period last year.

Balance Sheet

The Company's June 30, 2014 cash balance increased $6.2 million from December 31, 2013 to $40.2 million.  Total debt decreased $1.9 million from December 31, 2013 to $22.4 million on June 30, 2014.  Stockholders' equity increased $17.0 million to $264.2 million as of June 30, 2014 compared to $247.2 million as of December 31, 2013. 

Conference Call Information

Omega Protein will host a conference call on its second quarter 2014 financial results at 8:30 a.m., Eastern Time, on Thursday, August 7, 2014. The Company's senior management team will be available to discuss recent financial results and current business trends as well as respond to questions.

Please dial (877) 407-3982 domestically or (201) 493-6780 internationally to join the call. Interested parties may also listen to the webcast live over the Internet at www.omegaprotein.com.

A webcast replay of the conference call will be available beginning shortly after the conclusion of the call at www.omegaprotein.com and will be available for 30 days. A telephonic replay of the conference call will be available through August 21, 2014. Domestic listeners can dial (877) 870-5176, and international listeners may dial (858) 384-5517. The replay access code is 13586946.

About Omega Protein

Omega Protein Corporation (NYSE: OME) is a century old nutritional company that develops, produces and delivers healthy products throughout the world to improve the nutritional integrity of functional foods, dietary supplements and animal feeds.  Omega Protein's mission is to help people lead healthier lives with better nutrition through sustainably sourced ingredients such as highly-refined omega-3 rich fish oil, specialty proteins and nutraceuticals.

Forward Looking Statements

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: The statements contained in this press release that are not historical facts are forward-looking statements that involve a number of risks and uncertainties. Forward-looking information may be based on projections, predictions and estimates. Some statements in this press release may be forward-looking and use words like "may," "may not," "believes," "do not believe," "expects," "do not expect," "anticipates," "do not anticipate," "see," "do not see," "should," or other similar expressions. The actual results of future events described in any of these forward-looking statements could differ materially from those stated in the forward-looking statements. Important factors that could cause actual results to be materially different from those forward-looking statements include, among others: (1) the Company's ability to meet its raw material requirements through its annual menhaden harvest, which is subject to fluctuations due to natural conditions over which the Company has no control, such as varying fish population, fish oil yields, adverse weather conditions, natural and other disasters and disease; (2) the impact of laws and regulations that may be enacted that may restrict the Company's operations or the sale of the Company's products; (3) the impact of worldwide supply and demand relationships on prices for the Company's products; (4) the Company's expectations regarding demand and pricing for its products proving to be incorrect, and the effect of forward sales of products on the Company's financial results; (5) fluctuations in the Company's quarterly operating results due to the seasonality of the Company's business, estimates of standard cost for inventory and subsequent adjustments to such costs, and the Company's deferral of inventory sales based on worldwide prices for competing products; (6) the Company's ability to realize the anticipated benefits from its acquisitions in the human nutrition business, Nutegrity; (7) the Company's expectations regarding Nutegrity, its future prospects and the dietary supplement market or the human health and wellness segment generally, proving to be incorrect; (8) the cost of compliance with existing and future government regulations; (9) the impact of the Company's settlement with U.S. Attorney's Office on the Company's operations and financial results, including the impact of any failure to comply with the terms of the Company's probation or the limitations imposed on the Company's ability to secure government contracts or loans under the NFMS Title XI program; (10) the impact of the closure of the Company's Cameron, Louisiana processing plant on the Company's operations and financial results; (11) the cost of compliance or potential restrictions on sales caused by laws and regulations regarding fish meal or oil importation into foreign jurisdictions and (12) the effect of the previously reported July 28, 2014 explosion at the Company's Moss Point, Mississippi facility and subsequent temporary shut-down of that facility on the Company's business, results of operations or financial results.  Other factors are described in further detail in the Company's filings with the Securities and Exchange Commission, including its reports on Form 10-K, Form 10-Q and Form 8-K.

 

OMEGA PROTEIN CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET

(Dollars in thousands)




June 30,

2014


December 31,

2013

ASSETS







 Current assets:







          Cash and cash equivalents


$

40,214


$

34,059

          Receivables, net



31,304



21,140

          Inventories



79,860



94,339

          Deferred tax asset, net



904



1,062

          Prepaid expenses and other current assets



5,582



3,915








                Total current assets



157,864



154,515

Other assets, net



2,815



5,234

Property, plant and equipment, net



154,431



144,113

Goodwill



19,600



19,600

Other intangible assets, net



7,596



7,932

                Total assets


$

342,306


$

331,394






LIABILITIES AND STOCKHOLDERS' EQUITY














Current liabilities:







         Current maturities of long-term debt


$

2,564


$

3,112

         Accounts payable



4,074



5,380

         Accrued liabilities



25,910



29,145

              Total current liabilities



32,548



37,637

Long-term debt, net of current maturities



19,827



21,130

Deferred tax liability, net



20,375



19,351

Pension liabilities, net



3,246



4,117

Other long-term liabilities



2,142



1,929

                Total liabilities



78,138



84,164


Commitments and contingencies







Stockholders' equity:







        Preferred stock, $0.01 par value; 10,000,000 authorized shares; none issued                                     





        Common Stock, $0.01 par value; 80,000,000 authorized shares;

          21,099,066 and 20,804,189 shares issued and 21,094,443 and

          20,804,189 shares outstanding at June 30, 2014 and

          December 31, 2013, respectively



205



203

        Capital in excess of par value



138,557



136,428

        Retained earnings



131,411



116,807

        Treasury stock, at cost – 4,623 shares



(57)



        Accumulated other comprehensive loss



(5,948)



(6,208)

                Total stockholders' equity



264,168



247,230

                    Total liabilities and stockholders' equity


$

342,306


$

331,394










 

 

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

(In thousands, except per share amounts)




Three Months Ended


Six Months Ended



June 30,


June 30,



2014


2013


2014


2013

Revenues

$

71,913

$

41,777

$

135,413

$

90,700

Cost of sales


51,489


28,494


94,496


65,320

Gross profit


20,424


13,283


40,917


25,380










Selling, general, and administrative expense


6,526


6,030


12,619


12,473

Research and development expense


544


565


1,028


1,120

Loss related to plant closure


2,616



3,939


Loss (gain) on disposal of assets


(14)


(2)


233


374

Operating income


10,752


6,690


23,098


11,413

Interest income


5


2


13


10

Interest expense


(135)


(481)


(382)


(873)

Other expense, net


(118)


(98)


(174)


(181)

Income before income taxes


10,504


6,113


22,555


10,369










Provision for income taxes


3,871


2,123


7,951


3,534

Net income


6,633


3,990


14,604


6,835










Other comprehensive income (loss):









Energy swap adjustment, net of tax benefit of $10, $195, $20 and $56, respectively


(19)


(363)


(37)


(106)

Pension benefits adjustment, net of tax expense of

   $80, $135, $160 and $270, respectively


148


251


297


502

Comprehensive income

$

6,762

$

3,878

$

14,864

$

7,231



Basic earnings per share

$

0.32

$

0.20

$

0.70

$

0.34



Weighted average common shares outstanding


20,428


19,779


20,392


19,623



Diluted earnings per share

$

0.31

$

0.19

$

0.68

$

0.33


Weighted average common shares and potential

  common share equivalents outstanding


21,105


20,581


21,062


20,399


 

                                                                                                                         

OMEGA PROTEIN CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(Dollars in thousands)




Six Months Ended
June 30,



2014


2013

Cash flows from operating activities:





       Net income

$

14,604

$

6,835

       Adjustments to reconcile net income to net

          cash provided by operating activities:





        Depreciation and amortization


10,335


10,253

        Loss on plant closure


1,858


        Loss (gain) on disposal of assets


233


374

        Provisions for losses on receivables


24


24

        Share based compensation


944


891

        Deferred income taxes


1,110


1,409

        Changes in assets and liabilities:





                 Receivables


(10,188)


(2,671)

                   Inventories


14,271


(15,763)

                 Prepaid expenses and other current assets


(1,724)


(1,515)

                 Other assets


1,679


5,874

                 Accounts payable


(1,306)


(301)

                 Accrued liabilities


(1,718)


(2,536)

                 Pension liability, net


(482)


(246)

                 Other long term liabilities


(2)


30

                         Net cash provided by operating

                             activities


 

29,736


 

2,658

Cash flows from investing activities:





        Proceeds from disposition of assets


193


 

161

        Acquisition of Wisconsin Specialty Protein, net of

            cash acquired


 


 

(26,779)

        Capital expenditures


(23,268)


(12,897)

                         Net cash used in investing activities


(23,075)


(39,515)

Cash flows from financing activities:





        Principal payments of long-term debt


(1,851)


(1,569)

        Principal payments of capital lease obligation



(309)

        Purchase treasury stock at cost


(57)


 

        Proceeds from stock options exercised


946


3,048

        Excess tax benefit of stock options exercised


456


 

1,147

                         Net cash provided by (used in) financing

                             activities


(506)


 

2,317

Net increase (decrease) in cash and cash equivalents


6,155


(34,540)

Cash and cash equivalents at beginning of year


34,059


55,998

Cash and cash equivalents at end of period

$

40,214

$

21,458


The tables below present information about reported segments for the quarters ended June 30, 2014 and 2013 (in thousands): 

June 30, 2014


Animal
Nutrition


Human
Nutrition


Unallocated


Total

Revenue (1)           


$  65,264


$    6,649


  $        ―


$   71,913

Cost of sales        


45,501


5,988


            ―


51,489

Gross profit          


19,763


661


            ―


20,424

Selling, general and administrative expenses

  (including research and development)          


636


2,067


4,367


7,070

Loss related to plant closure             


2,616


          ―


            ―


2,616

Other (gains) and losses    


(14)


          ―


             ―


(14)

Operating income


$    16,525


$   (1,406)


$     (4,367)


$   10,752

Depreciation and amortization          


$      4,374


$        699


$            45


$     5,118

Identifiable assets               


$ 224,416


$  76,734


$    41,156


$ 342,306

Capital expenditures           


$      5,761


$    4,692


  $           ―


$   10,453

 

(1)

Excludes revenue from internal customers of $0.7 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

 

June 30, 2013


Animal
Nutrition


Human
Nutrition (
2)


Unallocated


Total

Revenue (3)           


$    34,453


$    7,324


  $        ―


$    41,777

Cost of sales        


22,786


5,708


            ―


28,494

Gross profit          


11,667


1,616


            ―


13,283

Selling, general and administrative expenses

  (including research and development)          


662


1,861


4,072


6,595

Other (gains) and losses    


(2)


          ―


            ―


(2)

Operating income


$    11,007


$     (245)


$    (4,072)


$     6,690

Depreciation and amortization          


$      4,472


$       632


$         172


$      5,276

Identifiable assets               


$ 227,462


$ 57,861


$   23,002


$ 308,325

Capital expenditures           


$      5,741


$       324


$         119


$      6,184

 

(2)

Includes revenues and related expenses for Wisconsin Specialty Protein ("WSP").



(3)

Excludes revenue from internal customers of $0.4 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

The tables below present information about reported segments for the six months ended June 30, 2014 and 2013 (in thousands).

June 30, 2014


Animal
Nutrition


Human
Nutrition


Unallocated


Total

Revenue(4)


$ 120,534


$  14,879


  $        ―


$ 135,413

Cost of sales


81,668


12,828


            ―


94,496

Gross profit


38,866


2,051


            ―


40,917

Selling, general and administrative expenses

  (including research and development)


1,189


3,988


8,470


13,647

Loss related to plant closure


3,939


            ―


            ―


3,939

Other (gains) and losses


42


191


            ―


233

Operating income (loss)


$    33,696


$  (2,128)


$   (8,470)


$   23,098

Depreciation and amortization


$      8,742


$   1,400


$         193


$   10,335

Identifiable assets


$ 224,416


$ 76,734


$   41,156


$ 342,306

Capital expenditures


$   10,358


$ 12,901


$             9


$   23,268

 

(4)

Excludes revenue from internal customers of $1.4 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

 

June 30, 2013


Animal
Nutrition


Human
Nutrition
(5)


Unallocated


Total

Revenue(6)


$   76,790


$  13,910


  $        ―


$   90,700

Cost of sales


53,880


11,440


            ―


65,320

Gross profit


22,910


2,470


            ―


25,380

Selling, general and administrative expenses

  (including research and development)


1,290


3,157


9,146


13,593

Other (gains) and losses


374


          ―


            ―


374

Operating income (loss)


$    21,246


$      (687)


$    (9,146)


$   11,413

Depreciation and amortization


$      8,821


$    1,070


$         362


$   10,253

Identifiable assets


$ 227,462


$ 57,861


$   23,002


$ 308,325

Capital expenditures


$   12,046


$       613


$        238


$   12,897

 

(5)

Includes revenues and related expenses for WSP from February 27, 2013 through June 30, 2013.



(6)

Excludes revenue from internal customers of $1.0 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

Adjusted EBITDA to Net Income Reconciliation
The following table (in thousands) provides a reconciliation of Adjusted EBITDA, a non-GAAP (Generally Accepted Accounting Principles) financial measure, to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, for the three months ended June 30, 2014, March 31, 2014 and June 30, 2013 and the six months ended June 30, 2014 and June 30, 2013:



Three Months Ended




June 30,

 2014


March 31,
2014


June 30,

 2013


Net Income

$

6,633

$

7,971

$

3,990


Reconciling items:








     Interest expense


105


216


451


     Income tax provision


3,871


4,080


2,123


     Depreciation and amortization


5,118


5,217


5,276


     Loss related to plant closure


2,616


1,323



     Loss (gain) on disposal of assets


(14)


247


(2)


Adjusted EBITDA

$

18,329

$

19,054

$

11,838


 




Six Months Ended





June 30,

 2014


June 30,

 2013


Net Income


$

14,604

$

6,835


Reconciling items:







   Interest expense



321


812


   Income tax provision



7,951


3,534


   Depreciation and amortization



10,335


10,253


   Loss (gain) on disposal of assets



3,939


               ―


   Net gain or loss on disposal of assets



233


374


Adjusted EBITDA


$

37,383

$

21,808


Adjusted EBITDA represents net income before interest expense, income tax, depreciation and amortization, loss related to plant closure and loss (gain) on disposal of assets. The Company has reported Adjusted EBITDA because it believes Adjusted EBITDA is a measure commonly reported and widely used by investors as an indicator of a Company's operating performance. The Company believes Adjusted EBITDA assists such investors in comparing a company's performance on a consistent basis. Adjusted EBITDA is not a calculation based on GAAP and should not be considered an alternative to net income in measuring our performance or used as an exclusive measure of cash flow because it does not consider the impact of working capital changes, capital expenditures, debt principal reductions and other sources and uses of cash which are disclosed in our consolidated statements of cash flows. Investors should carefully consider the specific items included in our computation of Adjusted EBITDA. While Adjusted EBITDA has been disclosed herein to permit a more complete comparative analysis of our operating performance relative to other companies, investors should be cautioned that Adjusted EBITDA as reported by us may not be comparable in all instances to Adjusted EBITDA as reported by us or by other companies. Adjusted EBITDA amounts may not be fully available for management's discretionary use, due to certain requirements to conserve funds for capital expenditures, debt service and other commitments, and therefore management relies primarily on our GAAP results. Adjusted EBITDA is not intended to represent net income as defined by GAAP and such information should not be considered as an alternative to net income, cash flow from operations or any other measure of performance prescribed by GAAP in the United States.

Adjusted Net Income and Diluted Earnings Per Share to Net Income Reconciliation
The following table (in thousands, except per share amounts) provides a reconciliation of Adjusted Net Income and Diluted Earnings Per Share, non-GAAP (Generally Accepted Accounting Principles) financial measures, to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, for the three months ended June 30, 2014, March 31, 2014 and June 30, 2013 and the six months ended June 30, 2014 and June 30, 2013:



Three Months Ended




June 30,

 2014


March 31,
2014


June 30,

 2013


Net Income

$

6,633

$

7,971

$

3,990


Reconciling items:








     Income tax provision prior to adjustments


3,871


4,080


2,123


     Loss related to plant closure


2,616


1,323



     Loss (gain) on disposal of assets


(14)


247


(2)


Adjusted income before income taxes


13,106


13,621


6,111


     Provision for income taxes after adjustments


4,830


4,612


2,122


Adjusted net income

$

8,276

$

9,009

$

3,989


Adjusted diluted earnings per share

$

0.38

$

0.42

$

0.19


                                                                                                                                          




Six Months Ended





June 30,

 2014


June 30,

 2013









Net Income


$

14,604

$

6,835


Reconciling items:







     Income tax provision prior to adjustments



7,951


3,534


     Loss related to plant closure



3,939


               ―


     Loss (gain) on disposal of assets



233


374


Adjusted income before income taxes



26,727


10,743


     Provision for income taxes after adjustments



9,422


3,661


Adjusted net income


$

17,305

$

7,082


Adjusted diluted earnings per share


$

0.80

$

0.34


Adjusted net income and Adjusted diluted earnings per share represent net income and diluted earnings per share without loss related to plant closure, loss (gain) on disposal of assets and taxes associated with these items. The Company has reported Adjusted net income and Adjusted diluted earnings per share because it believes these measures are widely used by investors as an indicator of a Company's operating performance. The Company believes Adjusted net income and Adjusted diluted earnings per share assist investors in comparing a company's performance on a consistent basis.  Adjusted net income and Adjusted diluted earnings per share are not calculations based on GAAP and should not be considered alternatives to net income or diluted earnings per share in measuring our performance. Investors should carefully consider the specific items included in our computation of Adjusted net income and Adjusted diluted earnings per share. While Adjusted net income and Adjusted diluted earnings per share has been disclosed herein to permit a more complete comparative analysis of our operating performance across time periods and relative to other companies, investors should be cautioned that these measures as reported by us may not be comparable in all instances to Adjusted net income and Adjusted diluted earnings per share as reported by us or by other companies. Adjusted net income and Adjusted diluted earnings per share are not intended to represent net income or diluted earnings per share as defined by GAAP and such information should not be considered as an alternative to net income, diluted earnings per share or any other measure of performance prescribed by GAAP in the United States.

Logo - http://photos.prnewswire.com/prnh/20120717/NE41641LOGO

SOURCE Omega Protein Corporation

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...
The past few years have brought a sea change in the way applications are architected, developed, and consumed—increasing both the complexity of testing and the business impact of software failures. How can software testing professionals keep pace with modern application delivery, given the trends that impact both architectures (cloud, microservices, and APIs) and processes (DevOps, agile, and continuous delivery)? This is where continuous testing comes in. D
Modern software design has fundamentally changed how we manage applications, causing many to turn to containers as the new virtual machine for resource management. As container adoption grows beyond stateless applications to stateful workloads, the need for persistent storage is foundational - something customers routinely cite as a top pain point. In his session at @DevOpsSummit at 21st Cloud Expo, Bill Borsari, Head of Systems Engineering at Datera, explored how organizations can reap the bene...
Digital transformation is about embracing digital technologies into a company's culture to better connect with its customers, automate processes, create better tools, enter new markets, etc. Such a transformation requires continuous orchestration across teams and an environment based on open collaboration and daily experiments. In his session at 21st Cloud Expo, Alex Casalboni, Technical (Cloud) Evangelist at Cloud Academy, explored and discussed the most urgent unsolved challenges to achieve f...
The dynamic nature of the cloud means that change is a constant when it comes to modern cloud-based infrastructure. Delivering modern applications to end users, therefore, is a constantly shifting challenge. Delivery automation helps IT Ops teams ensure that apps are providing an optimal end user experience over hybrid-cloud and multi-cloud environments, no matter what the current state of the infrastructure is. To employ a delivery automation strategy that reflects your business rules, making r...
The 22nd International Cloud Expo | 1st DXWorld Expo has announced that its Call for Papers is open. Cloud Expo | DXWorld Expo, to be held June 5-7, 2018, at the Javits Center in New York, NY, brings together Cloud Computing, Digital Transformation, Big Data, Internet of Things, DevOps, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone in...
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, discussed the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, application p...
No hype cycles or predictions of a gazillion things here. IoT is here. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, an Associate Partner of Analytics, IoT & Cybersecurity at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He also discussed the evaluation of communication standards and IoT messaging protocols, data...
Kubernetes is an open source system for automating deployment, scaling, and management of containerized applications. Kubernetes was originally built by Google, leveraging years of experience with managing container workloads, and is now a Cloud Native Compute Foundation (CNCF) project. Kubernetes has been widely adopted by the community, supported on all major public and private cloud providers, and is gaining rapid adoption in enterprises. However, Kubernetes may seem intimidating and complex ...
In his session at 21st Cloud Expo, Michael Burley, a Senior Business Development Executive in IT Services at NetApp, described how NetApp designed a three-year program of work to migrate 25PB of a major telco's enterprise data to a new STaaS platform, and then secured a long-term contract to manage and operate the platform. This significant program blended the best of NetApp’s solutions and services capabilities to enable this telco’s successful adoption of private cloud storage and launching ...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.